Roche´s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
(WorldNews Africa)

Basel, 20 October 2018 Roche`s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab-paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress, featured in the press programme and simultaneously...